Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
نویسندگان
چکیده
PURPOSE With the identification of new molecular targets and pathways, many new therapeutic approaches are being identified for potential application in the treatment of multiple myeloma. New chemical compounds and biologics have been developed against molecular targets with substantial scientific evidence that these targets are involved in myeloma development, progression, or relapse. To safely and rapidly bring these advances to bear on the disease, new preclinical models in cells and animals need to be established, as well as prioritization and standardization in current preclinical and clinical validation. An experts' roundtable was convened in November 2005 to discuss shortcomings in current preclinical models and discuss what models are needed to best validate therapeutics and combinations of therapies for multiple myeloma. CONCLUSIONS This exciting event brought together experts in compound validation, preclinical development, and experts in multiple myeloma from academic institutions and the pharmaceutical and biotechnology industries. The goals were to evaluate an algorithm for therapeutic validation and discuss in vitro modeling for target discovery, animal models for preclinical development, and models for testing drug combinations.
منابع مشابه
Apoptotic effect of apoptin gene transduction on multiple myeloma cell line
Introduction: Following the first description of multiple myeloma (MM), as the second most prevalent hematologic malignancy, multiple promising advances have paved the way to increase the long-lasting complete remission for patients. In the era of the novel therapeutic approaches, the cloning of the apoptosis-inducing genes into the genome of malignant cells has attracted tremendous attention. ...
متن کاملMultiple myeloma in a patient with suspected hyperparathyroidism
Multiple myeloma (MM) is a clonal B-lymphocyte neoplasm of terminally differentiated plasma cells. Imaging modalities which allow the recognition of the effects of myeloma cells on the skeletal system have been utilized for a long time. Herein, we represent a patient with generalized osteoporosis and hypercalcemia, who was referred for parathyroid scan, in whom the widespread bone marrow techne...
متن کاملIn vitro Effect of Pomalidomide on Bone Marrow Mononuclear Cells from Multiple Myeloma Patients
Background: Many features of anticancer drugs, including cytotoxicity and/or cytokine induction, are studied using cell lines orhuman blood leukocytes. However, in a disease such as multiple myeloma, most cancerous cells are resided within bone marrowmononuclear cells. In the present study, we investigated the effect of pomalidomide on apoptosis and IL-2 production of bonemarrow mononuclear cel...
متن کاملPyoderma Gangrenosum and Multiple Myeloma: A case report
A 79-year-old female came to skin clinic with an ulcer, 15×20 cm, on her left shin. The laboratory report and both the skin and bone marrow biopsies reports, showed pyoderma gangrenosum associated with multiple myeloma. The patient was referred to hematology clinic for treatment. Multiple myeloma has rarely been associated with pyoderma gangrenosum. Multiple myeloma should be investigated...
متن کاملNon Secretory Multiple Myeloma With HCV Infection: A Rare Case Entity
Multiple Myeloma is a neoplasm of B cell lineage characterized by excessive proliferation of abnormal plasma cells. It is characterized by a clinical pentad of 1) anemia, 2) a monoclonal protein in the serum or the urine or both, 3) bone leisons and or bone pain, 4) hypercalcemia >11.5g/dl and 5) renal insufficiency. Non secretory multiple myeloma is a rare variant of the classic form of multi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical cancer research : an official journal of the American Association for Cancer Research
دوره 12 22 شماره
صفحات -
تاریخ انتشار 2006